


U9 M D
R648



LOW MOLECULAR WEIGHT IgM IN HEALTH AND DISEASE

by

Peter John ROBERTS-THOMSON, M.B.,B.S.(Adelaide); D.Phil. (Oxford)

A thesis submitted for the degree of
Doctor of Medicine,
University of Adelaide

From the Department of Medicine,
University of Adelaide,

December, 1987

Reviewed by Board 10/3/88

INDEX

	Page
TITLE PAGE	i
INDEX	ii
STATEMENT OF ORIGINALITY	v
ACKNOWLEDGEMENTS	vi
ABSTRACT	viii
CHAPTER ONE: GENERAL INTRODUCTION	1
PENTAMERIC IgM	
Introduction	2
Physicochemical Properties	2
Biological Activities	5
Biosynthesis and Secretion	6
Phylogenetic Antiquity	8
Ontogeny	9
IgM Response in Disease	9
Membrane IgM	10
MONOMERIC OR LOW MOLECULAR WEIGHT IgM	12
Introduction	12
Physicochemical Properties	12
Methods of Detection	15
Occurrence and Clinical Significance	18
Theories for Occurrence	24
AIMS OF THESIS	27
CHAPTER TWO: PATIENTS, MATERIALS AND GENERAL METHODS	28
PATIENTS AND CONTROLS	29
STORAGE OF TEST SPECIMENS	30
IDENTIFICATION OF LOW MOLECULAR WEIGHT IgM	30
Filtration Chromatography and	
Nephelometry	30
Filtration Chromatography and ELISA	34
Immunoblotting	34
IgM SYNTHESIS IN VITRO	38
OTHER IMMUNOLOGICAL METHODS	40
STATISTICAL METHODS	40

	Page
CHAPTER THREE: DOES LOW MOLECULAR WEIGHT IgM OCCUR IN HEALTH?	42
SUMMARY	43
INTRODUCTION	43
SUBJECTS AND METHODS	44
RESULTS	45
DISCUSSION	45
CHAPTER FOUR: LOW MOLECULAR WEIGHT IgM IN RHEUMATOID ARTHRITIS AND OTHER RHEUMATIC DISORDERS	50
SUMMARY	51
INTRODUCTION	51
PATIENTS AND METHODS	53
RESULTS	55
DISCUSSION	65
CHAPTER FIVE: IN VITRO SYNTHESIS OF LOW MOLECULAR WEIGHT IgM IN RHEUMATOID ARTHRITIS	70
SUMMARY	71
INTRODUCTION	71
PATIENTS AND METHODS	72
RESULTS	75
DISCUSSION	80
CHAPTER SIX: APPEARANCE OF LOW MOLECULAR WEIGHT IgM DURING COURSE OF INFECTIVE ENDOCARDITIS	83
SUMMARY	84
INTRODUCTION	84
PATIENTS AND METHODS	85
RESULTS	86
DISCUSSION	89
CHAPTER SEVEN: LARGE QUANTITIES OF LOW MOLECULAR WEIGHT IgM IN MIXED CRYOGLOBULINAEMIA	92
SUMMARY	93
INTRODUCTION	93
PATIENTS AND METHODS	94
RESULTS	97
DISCUSSION	102

	Page
CHAPTER EIGHT: LOW MOLECULAR WEIGHT IgM IN SELECTIVE IgA DEFICIENCY	105
SUMMARY	106
INTRODUCTION	107
PATIENTS AND METHODS	107
RESULTS	109
DISCUSSION	113
CHAPTER NINE: LOW MOLECULAR WEIGHT IgM IN B CELL LYMPHOPROLIFERATIVE DISORDERS	117
SUMMARY	118
INTRODUCTION	119
PATIENTS AND METHODS	120
RESULTS	121
DISCUSSION	126
CHAPTER TEN: GENERAL DISCUSSION	129
OCCURRENCE OF LOW MOLECULAR WEIGHT IgM IN DISEASE	130
POSSIBLE ROLE IN PATHOGENESIS	131
POSSIBLE MECHANISMS FOR OCCURRENCE	135
APPENDIX	140
BIBLIOGRAPHY	142

ABSTRACT

This thesis examines the presence and role of low molecular weight (LMW) IgM in health and disease. LMW IgM is the naturally occurring monomeric subunit of pentameric IgM and has been previously observed in the blood from patients suffering from a variety of disorders but rarely in health.

In Chapter one there is a general description of the known physicochemical properties, function and role of both pentameric IgM and LMW IgM. Possible theories for the presence of LMW IgM in human disease are briefly discussed.

In Chapter two a description is given of three sensitive methods to detect and quantitate LMW IgM. One of these, viz immunoblotting, appears both sensitive and specific for LMW IgM and has revealed for the first time additional oligomers of IgM in sera containing LMW IgM.

In Chapter three sera from healthy controls and cord blood were examined for the presence of LMW IgM. This moiety was not found in sera from healthy subjects but was observed in low levels in a minority of cord sera.

Chapter four details a study of LMW IgM in sera and synovial fluid from patients with a variety of rheumatic disorders. In rheumatoid arthritis, 80% of the patients were found to have circulating LMW IgM and its levels correlated significantly with absolute IgM levels (measured nephelometrically) and with levels of rheumatoid factor and

circulating immune complexes. Separated column fractions containing LMW IgM were observed to contain IgM rheumatoid factor activity.

In Chapter five peripheral blood mononuclear cells taken from patients with active rheumatoid arthritis were found to secrete considerable quantities of LMW IgM in vitro. This did not occur with cells obtained from healthy controls. A significant correlation was found between the percentage of circulating LMW IgM and with the percentage of LMW IgM secreted in vitro. No evidence was obtained to suggest that LMW IgM occurred as a consequence of proteolytic breakdown of pentameric IgM.

In Chapters six, seven, eight and nine LMW IgM was observed in a varying proportion of patients suffering from infective endocarditis, mixed cryoglobulinaemia, selective IgA deficiency and in malignant B cell lymphoproliferative disorders but not in benign macroglobulinaemia. In 3 patients with mixed cryoglobulinaemia the LMW IgM was monoclonal and of the same light chain type (kappa) as the monoclonal pentameric IgM rheumatoid factor suggesting a common clonal origin.

In Chapter ten there is a brief discussion concerning the most likely explanations for the occurrence of LMW IgM in human disease and its possible role in the pathogenesis of these disorders. It is concluded that it is highly likely that LMW IgM has a pathogenic role in human disease. Further studies concerning this long neglected immunoglobulin are indicated as there is a distinct possibility that therapeutically reverting the disordered monomeric IgM humoral response

to a normal pentameric IgM response may result in resolution or amelioration of the disease.

Finally, the findings described in this thesis and from other observations are best accounted by postulating a defect in the assembly of the monomeric IgM subunits during pentameric IgM synthesis and secretion. Possible defects are discussed together with avenues of exploring such defects in future studies.